Literature DB >> 3046955

Dextromethorphan inhibits NMDA-induced convulsions.

J W Ferkany1, S A Borosky, D B Clissold, M J Pontecorvo.   

Abstract

Dextromethorphan, its metabolite dextrorphan, phencyclidine, ketamine, MK-801, 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and DL-2-amino-7-phosphonoheptanoic acid were evaluated for potency to antagonize N-methyl-D-aspartate-induced convulsions following intraperitoneal administration using male CF-1 mice. Whereas reference anticonvulsants (e.g., phenytoin) were ineffective in this model, dextromethorphan and all competitive and noncompetitive N-methyl-D-aspartate antagonists blocked seizures. The results are consistent with the interpretation that dextromethorphan elicits some of its pharmacological responses via an interaction with receptors for excitatory amino acids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046955     DOI: 10.1016/0014-2999(88)90707-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Dextromethorphan in molybdenum cofactor deficiency.

Authors:  G Kurlemann; O Debus; G Schuierer
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

2.  Convulsions induced by centrally administered NMDA in mice: effects of NMDA antagonists, benzodiazepines, minor tranquilizers and anticonvulsants.

Authors:  J L Moreau; L Pieri; B Prud'hon
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

3.  The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.

Authors:  Eun-Joo Shin; Seung-Yeol Nah; Won-Ki Kim; Kwang Ho Ko; Wang-Kee Jhoo; Yong-Kwang Lim; Joo Young Cha; Chieh-Fu Chen; Hyoung-Chun Kim
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 4.  Neuropsychopharmacological understanding for therapeutic application of morphinans.

Authors:  Eun-Joo Shin; Jau-Shyong Hong; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2010-10-30       Impact factor: 4.946

5.  Dextromethorphan differentially affects opioid antinociception in rats.

Authors:  Shiou-Lan Chen; Eagle Yi-Kung Huang; Lok-Hi Chow; Pao-Luh Tao
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

6.  Dextromethorphan in nonketotic hyperglycinaemia: metabolic variation confounds the dose-response relationship.

Authors:  G L Arnold; M L Griebel; J L Valentine; D M Koroma; G L Kearns
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

7.  Antagonism of various tonic convulsions in mice by dextrorphan and dizocilpine.

Authors:  N Akaike; N Himori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

8.  Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients.

Authors:  B Schmitt; R Netzer; S Fanconi; P Baumann; E Boltshauser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

9.  Effects of N6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice.

Authors:  D K Von Lubitz; I A Paul; M Carter; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1993-11-16       Impact factor: 4.432

10.  CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity.

Authors:  G E Fagg; H R Olpe; M F Pozza; J Baud; M Steinmann; M Schmutz; C Portet; P Baumann; K Thedinga; H Bittiger
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.